Table 2.
Description of hypophysitis at diagnosis (n = 17).
| Symptoms at Diagnosis, n (%) | |
|---|---|
| Fatigue | 16 (94.1) |
| Nausea, loss of appetite | 12 (70.6) |
| Headache | 3 (17.6) |
| Vision disorders | 0 (0) |
| Asymptomatic | 1 (5.9) |
| Hyponatremia, n (%) | 9 (52.9) |
| MRI showing abnormalities (among those with available data), n (%) | 0/14 (0) |
| Median time to onset after treatment initiation (range; weeks) | 28 (10–46) |
| Median number of courses before diagnosis (range) | 9 (3–21) |
| CTCAE grade, n (%) | |
| 1 | 1 (5.9) |
| 2 | 9 (52.9) |
| 3 | 7 (41.2) |
| 4–5 | 0 (0) |
| Cycle of ICI delayed due to hypophysitis, n (%) | 4 (23.5) |
| ICI discontinued due to hypophysitis, n (%) | 0 (0) |
| Pituitary deficiencies at diagnosis (among those with available data), n (%) | |
| ACTH deficiency | 17/17 (100) |
| Thyrotropic deficiency | 2/17 (11.8) |
| Gonadotropic deficiency | 3/16 (18.8) |
| Low IGF1 | 2/15 (13.3) |
MRI: magnetic resonance imaging, CTCAE: common terminology criteria for adverse events, ICI: immune checkpoint inhibitors, ACTH: adrenocorticotropic-hormone, IGF1: insulin-like growth factor 1.